About Epigenome Technologies

Founded and Inspired by Excellence

Epigenome Technologies emerged in 2022 as a spin-out from the pioneering Bing Ren lab at UC San Diego. Recognizing the transformative power of single-cell epigenetic profiling, our founders—Professor Bing Ren (UCSD epigenetics expert and former Harvard postdoc) and Pei Lin (with leadership experience at Illumina and the Salk Institute)—joined forces to bring cutting-edge single-cell and spatial DNA-binding solutions to the broader research community.

Mission & Vision

Our core mission is to illuminate the regulatory code of gene expression in individual cells, ultimately fueling breakthroughs in developmental disorders, progressive diseases like cancer, and the biology of aging. Over the next few years, we aim to solidify our position as the leading provider of high-resolution epigenetic services and kits, empowering researchers worldwide to make discoveries that drive better treatments and diagnostics.

Milestones & Achievements

• $6M in SBIR Grants: Sustaining robust R&D to enhance and expand our epigenetic toolkits.
• BRAIN Initiative: Our flagship technology, Paired-Tag, is actively utilized as part of this prestigious research program.
• High-Profile Publications: Our techniques feature in leading journals, including Nature Methods and Nature Communications, showcasing breakthroughs in single-cell epigenomics and metabolic stress response.

Technology & Differentiation

• First-Mover Advantage: We are among the very first to offer single-cell epigenetic profiling at scale, coupled with a unique multi-omic spatial solution.
• Broad Platform Compatibility: Seamless integration with numerous single-cell systems grants researchers the flexibility to choose a workflow that aligns with their lab infrastructure.
• Impact on Research & Medicine: By mapping regulatory mechanisms that underlie aberrant gene expression, we open new avenues for identifying therapeutic targets and delivering actionable clinical insights.

Looking Ahead

Our comprehensive approach to gene regulation sets us apart in a competitive biotech landscape. We’ve already proven that single-cell and spatial epigenetic profiling can unlock novel diagnostic markers and inform targeted therapies for conditions previously deemed intractable. As we continue to scale, we welcome conversations with potential acquirers and strategic partners who share our vision for revolutionizing the future of genomic research.